One of the main goals of Life4me+ — is to prevent new cases of HIV and other STIs, hepatitis C and tuberculosis.

The app helps to establish anonym communication between physicians and HIV-positive people. It allows you to conveniently organize your medication intake timetable and set concealed and personalized reminders.

All news

Archive

✕

12 November 2026, 10:00

161

Three Key Updates in HIV Treatment: EACS Guidelines

Three Key Updates in HIV Treatment: EACS Guidelines

The latest EACS HIV treatment recommendations bring three important changes: a broader eligibility for dolutegravir/lamivudine, a revised approach to the historical M184V resistance mutation, and expanded consideration of long-acting injectable therapy for selected patients ...

12 November 2026, 07:49

189

New HIV Antibody Treatment Shows Promise — But Who Would Benefit Most?

New HIV Antibody Treatment Shows Promise — But Who Would Benefit Most?

Could long-acting antibody treatment make HIV care easier for older adults? New findings presented at HIV Drug Therapy Glasgow 2026 suggest potential benefits for people managing multiple medications. But with only 20 participants and 24 weeks of follow-up, important questions ...

11 November 2026, 10:00

125

How Switzerland Prevented Hundreds of HIV Diagnoses With PrEP — and Who Is Still Being Left Behind

How Switzerland Prevented Hundreds of HIV Diagnoses With PrEP — and Who Is Still Being Left Behind

Switzerland’s national PrEP strategy may have helped avert an estimated 268 HIV diagnoses, according to findings presented at HIV Drug Therapy Glasgow 2026. But the benefits remain unevenly distributed: women account for just 1–2% of PrEP users, highlighting persistent gaps ...

10 November 2026, 10:00

176

Two Injections a Year Instead of a Daily Pill: New HIV Prevention Study Shows Striking Results

Two Injections a Year Instead of a Daily Pill: New HIV Prevention Study Shows Striking Results

Long-acting PrEP could make HIV prevention easier, but access remains a major challenge. The PURPOSE 5 study showed much higher treatment persistence with twice-yearly lenacapavir injections. However, researchers at HIV Drug Therapy Glasgow 2026 stressed that women remain ...

28 July 2026, 12:10

3994

Communities Call for Systemic Change in Access to HIV Treatment at Rio Pre-Conference

Communities Call for Systemic Change in Access to HIV Treatment at Rio Pre-Conference

Ahead of the official opening of AIDS 2026 in Rio de Janeiro, activists, experts and community representatives came together for the Treatment Pre-Conference, a five-hour event focused on the future of access to HIV treatment.

25 February 2026, 14:00

5837

Doravirine/Islatravir for Initial HIV Therapy: A Two-Drug Strategy in a Three-Drug World

Doravirine/Islatravir for Initial HIV Therapy: A Two-Drug Strategy in a Three-Drug World

At CROI 2026, much of the discussion around antiretroviral therapy focused on long-acting agents and treatment optimization in experienced populations. Yet another important presentation turned to the starting point of care: initial therapy in people newly diagnosed with ...

25 February 2026, 13:00

5308

Simplifying the Complex: Switching to BIC/LEN in Treatment-Experienced People with HIV

Simplifying the Complex: Switching to BIC/LEN in Treatment-Experienced People with HIV

At CROI 2026, among presentations focused on prevention strategies and new antiviral approaches, one oral session addressed a different — and very practical — question in HIV care: what about people who are already virologically suppressed but remain on complex, multi-tablet ...

24 February 2026, 15:00

5266

Syphilis, Superbugs and Self-Testing: STIs in the Era of HIV Control

Syphilis, Superbugs and Self-Testing: STIs in the Era of HIV Control

At CROI 2026, alongside discussions of metabolic therapies and inflammation, another plenary session brought the audience back to a more familiar reality. In her lecture, “Syphilis and Superbugs: Sexually Transmitted Infections in the Era of HIV Control,” Dr. Jeanne Marrazzo ...

24 February 2026, 14:00

5032

GLP-1 Receptor Agonists at CROI 2026: Revolution, Hype — or the Beginning of a New Era?

GLP-1 Receptor Agonists at CROI 2026: Revolution, Hype — or the Beginning of a New Era?

At CROI 2026, a conference traditionally focused on antiretroviral therapy, viral persistence and immune activation, one plenary session shifted the spotlight to a different kind of molecule — yet one that may reshape far more than diabetes care.

24 February 2026, 13:00

5871

Broadly Neutralizing Antibodies and Viral Rebound: Early Signals from the RIO Trial at CROI 2026

Broadly Neutralizing Antibodies and Viral Rebound: Early Signals from the RIO Trial at CROI 2026

At the 2026 Conference on Retroviruses and Opportunistic Infections (CROI), investigators presented preliminary data from the RIO trial suggesting that exposure to broadly neutralizing antibodies (bNAbs) may alter viral rebound dynamics following treatment interruption in ...

1 2 3...118